Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You must be 18 years of age or older.
• You must be able to understand and willing to sign a written consent form.
• You must have been on a stable or decreasing dose of steroids for at least 5 days before signing the consent form.
• Any side effects from previous cancer treatments must have mostly or fully cleared up before starting this trial.
• You must have a certain type of brain tumor (Astrocytoma IDH-mutant or Glioblastoma IDH-wildtype) or a solid tumor that has spread to the brain in a way that cannot be controlled by surgery or radiation.
• If you have a brain tumor, your ability to carry out daily activities must meet a minimum level measured by a standard medical scale (confirm with trial site).
• If you have another type of solid tumor, your ability to carry out daily activities must also meet a minimum level on a different standard scale (confirm with trial site).
• You must be expected to live for at least 3 more months.
• You must have had a brain MRI scan with contrast dye within 14 days of starting the trial drug.
• If you have a solid tumor that has spread, you must also have had a CT scan of your neck, chest, abdomen, and pelvis with contrast dye within 14 days of starting the trial drug.
• You must be willing and able to attend all study appointments and follow study procedures.
• If you have seizures, they must be well controlled on a stable dose of anti-seizure medication for at least 14 days before signing the consent form.
• Your blood counts and organ function (including kidneys, liver, and bone marrow) must be at healthy enough levels, checked through blood tests (confirm with trial site for specific values).
• If you are a woman who could become pregnant, or a man, you must agree to use effective contraception starting 30 days before the first dose, throughout the study, and for 90 days after finishing treatment.
• If you are a woman who could become pregnant, you must have a negative pregnancy blood test within 7 days before receiving the trial drug.
• Depending on which phase of the trial you are joining, you may need to have measurable disease visible on scans, and/or be receiving one of the specific approved standard treatments alongside the trial drug (confirm with trial site).

Who may not be able to join:

• You have cancer that has spread to the spinal cord itself.
• You have cancer that has spread to the membranes surrounding the brain or spinal cord (meninges or leptomeninges).
• You received a focused type of radiation therapy to brain tumors within 2 weeks before starting the trial drug.
• You have had another cancer diagnosed within the past 5 years, except for certain common skin cancers (basal cell or squamous cell carcinoma of the skin).
• You have a heart condition involving an abnormal heart rhythm measurement (QTcF greater than 470 ms), a history of certain heart rhythm risk factors such as heart failure or low potassium, or you take medications known to affect heart rhythm (confirm with trial site).
• You had surgery within 7 days before signing the consent form.
• Side effects from previous chemotherapy, immunotherapy, or radiation have not sufficiently cleared up.
• You have previously been treated with a substance called perillyl alcohol.
• You have a known allergy to perillyl alcohol.
• In Phase 1 only: you are currently receiving any other anti-cancer treatment.
• In Phase 2a or 2b only: you are receiving a standard cancer treatment that is not on the trial's approved list.
• In Phase 2b only: if you have the specific brain tumor types mentioned, your tumor has come back or progressed more than once.

Important: Always verify eligibility with the trial site directly before applying.